ICI-204,219

Known as: ICI 204,219, ICI 204219, ICI-204219 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-1999
0519891999

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
The efficacy and safety of single oral doses of the leukotriene D4-receptor antagonist, ICI 204,219, were tested in subjects with… (More)
Is this relevant?
1994
1994
The efficacy of 6 wk of therapy with oral ICI 204,219, a selective leukotriene D4 (LTD4) receptor antagonist, was evaluated in… (More)
Is this relevant?
1994
1994
The hypothesis that cysteinyl-leukotrienes (LTC4, LTD4 and LTE4) are mediators of allergen-induced airway obstruction in… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1993
1993
Leukotrienes are potent bronchoconstrictors, and they are present in the airways of asthmatic subjects. Leukotriene receptor… (More)
Is this relevant?
1993
1993
The peptide-leukotriene antagonist, ICI 204,219 [4-(5-cyclopentyloxycarbonylamino-lmethylindol-3-ylmethyl )-3-methoxy-n-o… (More)
Is this relevant?
1993
1993
We determined whether platelet-activating factor (PAF) caused bronchoconstriction through the release of leukotrienes (LT) by… (More)
Is this relevant?
1992
1992
The sulfidopeptide leukotrienes C4, D4, and E4 are released from mast cells in response to allergen challenge and may be involved… (More)
Is this relevant?
1992
1992
We studied the effect of a single oral dose of ICI 204,219 on subject response to bronchoprovocation and quantitative skin… (More)
Is this relevant?
1990
1990
ICI 204,219 (4-(5-cyclopentyloxycarbonylamino-1-methylindol-3-ylmethy l)-3- methoxy-N-o-tolylsulfonylbenzamide) was designed as a… (More)
Is this relevant?
1990
1990
The sulfidopeptide leukotrienes may play a role in the pathogenesis of asthma. Previous clinical trials with leukotriene… (More)
Is this relevant?